---
figid: PMC4253418__oncotarget-05-9049-g007
figlink: /pmc/articles/PMC4253418/figure/F7/
number: Figure 7
caption: 'Beginning with phospho-RTK and other kinase screening and functional proteomic
  analysis with RPPA on LTED ER-positive breast cancer cells with or without treatment
  with fulvestrant, dasatinib or MK0646 and combining the published reports, a resultant
  pathway signature mediated by LTED and the targeting therapies is illustrated. After
  targeting estrogen therapy, small number of tumor cells acquired adaptive capacities,
  including: 1) compensatory increase ER Expression; 2) activation of multiple receptor
  tyrosine kinases; 3) signal crosstalk between ER and growth factor receptor pathways.
  Fulvestrant down-regulates ER and suppresses the signal crosstalk (pink frame).
  Dasatinib targets multiple RTKs, including EphAs, HGRR, RYK as well as non-receptor
  tyrosine kinases. Combination of fulvestrant and dasatinib inhibits cancer cell
  proliferation and invasion by blocking multiple receptor or non-receptor tyrosine
  kinase and targeting ER and crosstalk between ER and growth factor signaling. MK0646
  targets IGF1R and Insulin R pathway, however, somehow activates RYK and Wnt pathway,
  leading β-catenin accumulation and relocates in nuclei, where, in turn, induce transcription
  of c-Myc and cyclin D1.'
pmcid: PMC4253418
papertitle: Targeting tyrosine-kinases and estrogen receptor abrogates resistance
  to endocrine therapy in breast cancer.
reftext: Shuying Liu, et al. Oncotarget. 2014 Oct;5(19):9049-9064.
pmc_ranked_result_index: '34120'
pathway_score: 0.954685
filename: oncotarget-05-9049-g007.jpg
figtitle: Targeting tyrosine-kinases and estrogen receptor abrogates resistance to
  endocrine therapy in breast cancer
year: '2014'
organisms: Homo sapiens
ndex: 5a491228-dee0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4253418__oncotarget-05-9049-g007.html
  '@type': Dataset
  description: 'Beginning with phospho-RTK and other kinase screening and functional
    proteomic analysis with RPPA on LTED ER-positive breast cancer cells with or without
    treatment with fulvestrant, dasatinib or MK0646 and combining the published reports,
    a resultant pathway signature mediated by LTED and the targeting therapies is
    illustrated. After targeting estrogen therapy, small number of tumor cells acquired
    adaptive capacities, including: 1) compensatory increase ER Expression; 2) activation
    of multiple receptor tyrosine kinases; 3) signal crosstalk between ER and growth
    factor receptor pathways. Fulvestrant down-regulates ER and suppresses the signal
    crosstalk (pink frame). Dasatinib targets multiple RTKs, including EphAs, HGRR,
    RYK as well as non-receptor tyrosine kinases. Combination of fulvestrant and dasatinib
    inhibits cancer cell proliferation and invasion by blocking multiple receptor
    or non-receptor tyrosine kinase and targeting ER and crosstalk between ER and
    growth factor signaling. MK0646 targets IGF1R and Insulin R pathway, however,
    somehow activates RYK and Wnt pathway, leading β-catenin accumulation and relocates
    in nuclei, where, in turn, induce transcription of c-Myc and cyclin D1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - AKT1
  - AKT2
  - APC
  - AXIN2
  - AXIN1
  - MAPK11
  - MAPK9
  - MAPK10
  - PIK3CA
  - AKT3
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - CTNNB1
  - MAPK3
  - MAPK8
  - CCND1
  - ESR1
  - GSK3B
  - HGF
  - PIK3R3
  - PRKD3
  - PDGFB
  - MAP2K1
  - IGF1
  - MAPK13
  - MAPK14
  - PRKCH
  - MYC
  - TF
  - WNT3
  - PRKCQ
  - PRKCZ
  - ARAF
  - PDGFA
  - MAPK12
  - MAP2K2
  - PDGFC
  - PDGFD
  - MTOR
  - MAPK1
  - BMPR2
  - PIK3R4
  - PRKCI
  - RAF1
  - HRAS
  - BRAF
  - SRC
  - NRAS
  - PIK3R6
  - PIK3R5
  - KRAS
  - RYK
  - Estrogen
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN2
  entrez: '8313'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN1
  entrez: '8312'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: B-catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: CyclinD1
  symbol: Cyclin-D1
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: ERA
  symbol: ER-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: ESR1
  entrez: '2099'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: (HGF,
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: (HGF,PDGF,etc)
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: MĘK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: (IGF1,
  symbol: IGF1
  source: hgnc_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: cMyc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: TF.
  symbol: TF
  source: hgnc_symbol
  hgnc_symbol: TF
  entrez: '7018'
- word: Wnt3.
  symbol: WNT3
  source: hgnc_symbol
  hgnc_symbol: WNT3
  entrez: '7473'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: (HGF,PDGF,etc)
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MĘK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: (HGF,PDGF,etc)
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: (HGF,PDGF,etc)
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: talk
  symbol: T-ALK
  source: hgnc_alias_symbol
  hgnc_symbol: BMPR2
  entrez: '659'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RYK
  symbol: RYK
  source: hgnc_symbol
  hgnc_symbol: RYK
  entrez: '6259'
chemicals:
- word: Estrogen
  source: MESH
  identifier: D004967
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
